Cavitation Technologies, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OQB
Cavitation Technologies, Inc. reported a substantial net loss of $734,000 for the six months ended December 31, 2025, driven by a sharp decline in revenue and increased operating expenses, raising significant going concern doubts.
OQB
Cavitation Technologies, Inc. reported increased net losses and a significant cash burn, raising substantial doubt about its ability to continue as a going concern.
OQB
Cavitation Technologies reports a net income of $122,000 for the nine months ended March 31, 2025, despite a significant decrease in revenue due to a patent assignment with Desmet.
OQB
Cavitation Technologies, Inc. reports a net income of $352,000 for the six months ended December 31, 2024, primarily due to a gain on patent assignment to Desmet Ballestra.
OQB
10-Q: Cavitation Technologies Reports Q1 2025 Results, Highlights Patent Monetization and Strategic Shift
Cavitation Technologies reports a net loss of $227,000 for the quarter ended September 30, 2024, while also highlighting a significant patent assignment agreement with Desmet and a strategic shift towards new markets.
OQB
10-Q: Cavitation Technologies Reports Strong Revenue Growth in Q3 2024, But Going Concern Doubts Remain
Cavitation Technologies, Inc. saw a significant increase in revenue and a return to profitability in Q3 2024, driven by a new licensing agreement, but concerns about the company's ability to continue as a going concern persist.
OQB
Cavitation Technologies saw a significant increase in revenue during the second quarter of fiscal year 2024, but continues to face financial challenges and going concern doubts.